Purple Biotech Receives Intention to Grant a European Patent Covering NT219 Combinations with Immunotherapies or MEK Inhibitors to Overcome Tumor Resistance

A Phase 2 study for NT219 in combination with immunotherapy is being conducted in collaboration with the University of Colorado

REHOVOT, Israel, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced that the Examining Division of the European Patent Office has issued an intention to grant a European Patent for Application No. 20168234.1, titled 'Combinations of IRS/STAT3 Dual Modulators and Anti-Cancer Agents for Treating Cancer'.

Read more at globenewswire.com